NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.12. The medical instruments supplier had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.54 million. View TransEnterix's earnings history.

1 Wall Street analysts have issued twelve-month price objectives for TransEnterix's stock. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 142.1% from the stock's current price. View analysts' price targets for TransEnterix.

News coverage about TRXC stock has been trending very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutTransEnterix.

TransEnterix saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 3,150,000 shares, a drop of 6.3% from the April 15th total of 3,360,000 shares. Based on an average trading volume of 1,750,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 9.8% of the company's shares are sold short. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Relevium Technologies (RLV), Akers Biosciences (AKR), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY), Commerzbank (CZMWY) and CONVATEC GRP PL/ADR (CNVVY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.72%), BlackRock Inc. (2.51%), First Trust Advisors LP (1.31%), Russell Investments Group Ltd. (0.89%), State Street Corp (0.60%) and Perkins Capital Management Inc. (0.49%). Company insiders that own TransEnterix stock include Andrea Biffi, Joseph P Slattery, Todd Pope, William N Starling Jr and William N Starling, Jr. View institutional ownership trends for TransEnterix.

TRXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Morgan Stanley. View insider buying and selling activity for TransEnterix.

TRXC stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Russell Investments Group Ltd., State Street Corp, Perkins Capital Management Inc., BlackRock Inc., Invesco Ltd., Two Sigma Investments LP, and First Trust Advisors LP. View insider buying and selling activity for TransEnterix.

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.41.

TransEnterix has a market capitalization of $21.41 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.